Mumbai, Thursday, January 15, 2026 – Cipla Limited (BSE: 500087 | NSE: CIPLA) said that the supply of Lanreotide Injection, one of its top three products in the US market, will remain temporarily constrained due to a production pause at its overseas manufacturing partner’s facility. The company expects supplies to resume in the first half of FY 2026–27.
Lanreotide Supply Update
Lanreotide Injection for the US market is manufactured by Pharmathen International S.A., which is the exclusive supplier for Cipla’s US subsidiary. Following a recent inspection at the partner’s Rodopi, Greece manufacturing facility, production has been temporarily paused to support ongoing remediation efforts.Cipla said that until manufacturing operations restart, Lanreotide will continue to be available in limited quantities, subject to quality clearance. The company added that it is working closely with its partner to restore stable and reliable supply at the earliest.
About the Company
Cipla Limited is a global pharmaceutical company with a strong presence across respiratory, cardiac, anti-retroviral, urology, and oncology therapies. The company has a significant footprint in India, the US, and other regulated and emerging markets, with a focus on affordable and high-quality medicines.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.